Combined Therapeutics

The world can’t wait for breakthroughs. Join the brightest in biotech and transform ideas into impact. Register now.

?? Next up we welcomed Derek O'Hagan, Senior Advisor R&D at GSK, who presented on ‘The Role of Adjuvants in Vaccine Development.’ Derek provided a comprehensive review of the mechanisms and science behind adjuvants, discussing how they enhance immune responses and their potential to improve the performance of RNA vaccines. ??? He also shared insights into the future outlook, exploring what the next generation of adjuvants might look like. We look forward to continued discussions on this vital topic! #mRNA #Vaccines #Adjuvants #Immunology #Innovation #Biotech #GSK

Vaccine-based protection from COVID-19 wanes over time, especially in older adults. To address this problem, NIAID-supported researchers added mRNA encoding immune protein IL-12 to a COVID-19 mRNA vaccine, raising immune responses in aged mice to levels akin to those seen in young adult mice. IL-12 is important for responding well to vaccination, but natural production of this protein declines as people and mice age. For safety, researchers designed the adjuvant so only the muscle where it is injected makes the protein. These findings could mark a step toward better COVID-19 mRNA vaccines for older adults. Learn more: https://lnkd.in/eTThbX9Q #NIH #NIAID #COVID19 #mRNA #immunology #science #research #ScienceTranslationalMedicine Boston Children's Hospital Brigham and Women's Hospital Combined Therapeutics

Our work highlighted by the NIH!

Thank you to Science Magazine for highlighting our work, to tailor mRNA vaccines for vulnerable populations and advance adjuvant innovation: - To improve immune durability with adjuvanted mRNA vaccine which amplified vaccine responses even at very low vaccine doses - To limit expression of the mRNAs to muscle, potentially reducing systemic reactogenicity after vaccination - Overall, we prove that mRNA vaccines, like their protein counterparts, highly benefit from adjuvantation

Published now in the journal of Science Translational Medicine! PVP researchers Byron Brook, David Dowling, Ph.D., and Ofer Levy, MD PhD along with Valerie Duval and Romain Micol from Combined Therapeutics discover a novel adjuvant system called IL-12 MOP and highlight its importance in #mRNA vaccine technology, capable of increasing its durability and effectiveness. Read the full article here: https://lnkd.in/eTThbX9Q

"Creating the next generation of mRNA vaccines" - Thank you to Science Magazine / AAAS for highlighting our work, to tailor mRNA vaccines for vulnerable populations and advance adjuvant innovation, on the Cover of this week's issue of #ScienceTranslationalMedicine! - https://lnkd.in/etmfCXgk - On the Cover - "An Adjuvant Advance": - To improve immune durability, we adjuvanted the BNT162b2 SARS-CoV-2 vaccine with a mRNA encoding IL-12p70, which amplified vaccine responses even at very low vaccine doses. - The team also developed a strategy to limit expression of the mRNAs to muscle, potentially reducing systemic reactogenicity after vaccination. - Overall, we prove that mRNA vaccines, like their protein counterparts, highly benefit from adjuvantation. Led by the fantastic team of Byron Brook, Valerie D. and Romain Micol - Combined Therapeutics, Precision Vaccines Program, Boston Children's Hospital and Harvard Medical School. We appreciate the support from the National Institute of Allergy and Infectious Diseases (NIAID).